Long-term efficacy and safety for the complement factor B inhibitor iptacopan in IgA nephropathy.
Brad H Rovin, Hernán Trimarchi, Bart Maes...
https://pubmed.ncbi.nlm.nih.gov/42909451/Actively Recruiting
Led by Novartis Pharmaceuticals · Updated on 2026-10-05
540
Participants Needed
161
Research Sites
N/A
Total Duration
Researchers are evaluating the long-term safety and tolerability of open-label iptacopan in adults with primary IgA nephropathy who have completed earlier clinical trials CLNP023X2203 or CLNP023A2301. This Phase III rollover extension program allows participants to continue treatment while gathering additional data on the drugs effects over time. The study aims to assess the ongoing impact of iptacopan on disease progression until marketing authorization or other specified conditions are met. Participants receive iptacopan capsules at a dose of 200 mg taken orally twice daily. Treatment continues until one of several conditions occurs, including completion of 3 years from the last participants first visit, loss of benefit as judged by the investigator, a change in the drugs benefit-risk profile, need for dialysis or kidney transplant, or drug availability through commercial channels. This open-label design provides continuous access to iptacopan while monitoring long-term effects. During the study, participants undergo safety assessments including monitoring for adverse events, vital sign changes, ECG abnormalities, and laboratory test results from the first dose until 7 days after the last dose. Efficacy evaluations are conducted every 6 months to track kidney function and proteinuria levels. The total participation period may last up to three years, offering detailed data on the drugs long-term safety and clinical impact in primary IgA nephropathy.
CONDITIONS
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Novartis Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Iptacopan (investigational) | Supportive care (current guideline‑based) |
|---|---|---|
| What it is | An investigational oral complement factor B inhibitor (iptacopan) taken twice daily in participants continuing from prior iptacopan trials | Use of maximally tolerated ACE inhibitor or angiotensin II receptor blocker to reduce proteinuria and slow kidney function loss as recommended by current KDIGO guideline |
| Role in the trial | Study treatment received in the rollover extension program (REP) | Background regimen required for all participants during the trial |
| Primary use | To evaluate long‑term safety and tolerability of iptacopan in patients with IgA nephropathy | Manage proteinuria and preserve kidney function as supportive therapy |
| How it is given or performed | Oral capsule 200 mg taken twice daily | Oral ACE inhibitor or ARB at maximally tolerated doses per guideline |
| Evidence status | Long‑term safety and tolerability being evaluated; efficacy data emerging from related randomized trials show slowed eGFR decline with iptacopan versus placebo | Supportive therapy with ACEi or ARB reduces proteinuria and slows disease progression according to guideline based on substantial evidence |
| Important risks | Safety is still under assessment; prior trial data report similar overall adverse event rates compared to placebo, with somewhat higher serious infections | Risks of ACEi or ARB include hyperkalemia and reduced kidney perfusion, which are well‑known and monitored |
| Important limitations | Open‑label extension lacks a concurrent control arm; longer‑term outcomes beyond tolerability need confirmation in randomized trials | Supportive care alone does not address underlying disease mechanisms and may not fully prevent progression |
| Patient impact | Emerging evidence suggests slowing of kidney function decline and reduction in progression to composite kidney‑failure endpoints compared with placebo | Supportive care helps slow disease progression and reduce proteinuria, providing foundational protection of kidney function |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to 3 years
Participants receive open-label iptacopan 200 mg capsules twice daily and continue treatment until specified conditions occur such as benefit loss, kidney failure, or drug availability.
Visits every 6 months for assessments
Duration - 7 days after last dose
Safety and efficacy are monitored including adverse events, vital signs, ECG, lab tests, and kidney function measurements.
1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Brad H Rovin, Hernán Trimarchi, Bart Maes...
https://pubmed.ncbi.nlm.nih.gov/42909451/Novartis Pharmaceuticals
Lead Sponsor